Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review

 

 Buy Article Permissions and Reprints

Abstract

The endocannabinoid system shows promise as a novel target for treating psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid, has been investigated in several psychiatric conditions, with diverse effects and an excellent safety profile compared to standard treatments. Even though the body of evidence from randomised clinical trials is growing, it remains relatively limited in most indications. This review comprises a comprehensive literature search to identify clinical studies on the effects of CBD in psychiatric conditions. The literature search included case studies, case reports, observational studies, and RCTs published in English before July 27, 2023, excluding studies involving nabiximols or cannabis extracts containing CBD and ∆⁹-tetrahydrocannabinol. Completed studies were considered, and all authors independently assessed relevant publications.

Of the 150 articles identified, 54 publications were included, covering the effects of CBD on healthy subjects and various psychiatric conditions, such as schizophrenia, substance use disorders (SUDs), anxiety, post-traumatic stress disorder (PTSD), and autism spectrum disorders. No clinical studies have been published for other potential indications, such as alcohol use disorder, borderline personality disorder, depression, dementia, and attention-deficit/hyperactivity disorder. This critical review highlights that CBD can potentially ameliorate certain psychiatric conditions, including schizophrenia, SUDs, and PTSD. However, more controlled studies and clinical trials, particularly investigating the mid- to long-term use of CBD, are required to conclusively establish its efficacy and safety in treating these conditions. The complex effects of CBD on neural activity patterns, likely by impacting the endocannabinoid system, warrant further research to reveal its therapeutic potential in psychiatry.

^† Co-senior authorship: Cathrin Rohleder, F. Markus Leweke

Publication History

Received: 25 August 2023
Received: 22 November 2023

Accepted: 04 December 2023

Article published online:
24 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Arias D, Saxena S, Verguet S. Quantifying the global burden of mental disorders and their economic value. eClinicalMedicine 2022; 54: 101675 DOI: 10.1016/j.eclinm.2022.101675.
  CrossrefPubMedGoogle Scholar
• 2 GBD. 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022; 9: 137-150 DOI: 10.1016/s2215-0366(21)00395-3.
  CrossrefPubMedGoogle Scholar
• 3 Zamberletti E, Rubino T, Parolaro D. The endocannabinoid system and schizophrenia: Integration of evidence. Curr Pharm Des 2012; 18: 4980-4990 DOI: 10.2174/138161212802884744.
  CrossrefPubMedGoogle Scholar
• 4 Lu H-C, Mackie K. Review of the endocannabinoid system. Biol Psychiatry Cognitive Neurosci Neuroimaging 2020; 6: 607-615 DOI: 10.1016/j.bpsc.2020.07.016.
  CrossrefPubMedGoogle Scholar
• 5 Laprairie RB, Bagher AM, Kelly MEM. et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Brit J Pharmacol 2015; 172: 4790-4805 DOI: 10.1111/bph.13250.
  CrossrefPubMedGoogle Scholar
• 6 Rohleder C, Müller JK. Pharmakologie von cannabis und cannabinoiden. Psychopharmakologie 2020; 27: 105-113
  PubMedGoogle Scholar
• 7 Kaplan JS, Stella N, Catterall WA. et al. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA 2017; 114: 11229-11234 DOI: 10.1073/pnas.1711351114.
  CrossrefPubMedGoogle Scholar
• 8 Vilela LR, Lima IV, Kunsch ÉB. et al. Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. Epilepsy Behav 2017; 75: 29-35 DOI: 10.1016/j.yebeh.2017.07.014.
  CrossrefPubMedGoogle Scholar
• 9 O’Sullivan SE. Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors. Brit J Pharmacol 2007; 152: 576-582 DOI: 10.1038/sj.bjp.0707423.
  CrossrefPubMedGoogle Scholar
• 10 Leweke FM, Piomelli D, Pahlisch F. et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2: e94 DOI: 10.1038/tp.2012.15.
  CrossrefPubMedGoogle Scholar
• 11 Bisogno T, Hanuš L, Petrocellis LD. et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Brit J Pharmacol 2001; 134: 845-852 DOI: 10.1038/sj.bjp.0704327.
  CrossrefPubMedGoogle Scholar
• 12 Elmes MW, Kaczocha M, Berger WT. et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD)*. J Biol Chem 2015; 290: 8711-8721 DOI: 10.1074/jbc.m114.618447.
  CrossrefPubMedGoogle Scholar
• 13 Russo EB, Burnett A, Hall B. et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037-1043 DOI: 10.1007/s11064-005-6978-1.
  CrossrefPubMedGoogle Scholar
• 14 Rock EM, Bolognini D, Limebeer CL. et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2012; 165: 2620-2634 DOI: 10.1111/j.1476-5381.2011.01621.x.
  CrossrefPubMedGoogle Scholar
• 15 Sonego AB, Gomes FV, Bel EAD. et al. Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice. Behav Brain Res 2016; 309: 22-28 DOI: 10.1016/j.bbr.2016.04.042.
  CrossrefPubMedGoogle Scholar
• 16 Gomes FV, Resstel LBM, Guimarães FS. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology 2011; 213: 465-473 DOI: 10.1007/s00213-010-2036-z.
  CrossrefPubMedGoogle Scholar
• 17 Leweke FM, Mueller JK, Lange B. et al. Role of the endocannabinoid system in the pathophysiology of schizophrenia: Implications for pharmacological intervention. CNS Drugs 2018; 32: 605-619 DOI: 10.1007/s40263-018-0539-z.
  CrossrefPubMedGoogle Scholar
• 18 Crocq M-A. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci 2020; 22: 223-228 DOI: 10.31887/dcns.2020.22.3/mcrocq.
  CrossrefPubMedGoogle Scholar
• 19 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372: n71 DOI: 10.1136/bmj.n71.
  CrossrefPubMedGoogle Scholar
• 20 Zuardi A, Crippa J, Dursun S. et al. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol 2010; 24: 135-137 DOI: 10.1177/0269881108096521.
  CrossrefPubMedGoogle Scholar
• 21 Arciniegas DB. Psychosis. Continuum (Minneap Minn) 2015; 21: 715-736 DOI: 10.1212/01.con.0000466662.89908.e7.
  CrossrefPubMedGoogle Scholar
• 22 Perälä J, Suvisaari J, Saarni SI. et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64: 19-28 DOI: 10.1001/archpsyc.64.1.19.
  CrossrefPubMedGoogle Scholar
• 23 Ľupták M, Michaličková D, Fišar Z. et al. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J Psychiatry 2021; 11: 277-296 DOI: 10.5498/wjp.v11.i7.277.
  CrossrefPubMedGoogle Scholar
• 24 Leweke FM, Giuffrida A, Wurster U. et al. Elevated endogenous cannabinoids in schizophrenia. NeuroReport 1999; 10: 1665-1669 DOI: 10.1097/00001756-199906030-00008.
  CrossrefPubMedGoogle Scholar
• 25 Zuardi AW, Morais SL, Guimarães FS. et al. Antipsychotic effect of cannabidiol. J Clin psychiatry 1995; 56: 485-486
  PubMedGoogle Scholar
• 26 Zuardi AW, Hallak JEC, Dursun SM. et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006; 20: 683-686 DOI: 10.1177/0269881106060967.
  CrossrefPubMedGoogle Scholar
• 27 Zuardi A, Crippa J, Hallak J. et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 2009; 23: 979-983 DOI: 10.1177/0269881108096519.
  CrossrefPubMedGoogle Scholar
• 28 Makiol C, Kluge M. Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol. Aust N Zealand J Psychiatry 2019; 53: 262-262 DOI: 10.1177/0004867418815982.
  CrossrefPubMedGoogle Scholar
• 29 Leweke FM, Rohleder C, Gerth CW. et al. Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled, randomized clinical trial. Front Pharmacol 2021; 12: 614811 DOI: 10.3389/fphar.2021.614811.
  CrossrefPubMedGoogle Scholar
• 30 McGuire P, Robson P, Cubala WJ. et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry 2018; 175: 225-231 DOI: 10.1176/appi.ajp.2017.17030325.
  CrossrefPubMedGoogle Scholar
• 31 Boggs DL, Surti T, Gupta A. et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl) 2018; 235: 1923-1932 DOI: 10.1007/s00213-018-4885-9.
  CrossrefPubMedGoogle Scholar
• 32 van Boxel R, Gangadin SS, Janssen H. et al. The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder. J Psychiatr Res 2023; 163: 93-101 DOI: 10.1016/j.jpsychires.2023.05.019.
  CrossrefPubMedGoogle Scholar
• 33 Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S. et al. Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: A multimodal, multisite machine learning analysis. JAMA Psychiatry 2018; 75: 1156-1172 DOI: 10.1001/jamapsychiatry.2018.2165.
  CrossrefPubMedGoogle Scholar
• 34 Carrión RE, McLaughlin D, Goldberg TE. et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry 2013; 70: 1133-1142 DOI: 10.1001/jamapsychiatry.2013.1909.
  CrossrefPubMedGoogle Scholar
• 35 Carpenter WT. Attenuated psychosis syndrome: Need for debate on a new disorder. Psychopathology 2014; 47: 287-291 DOI: 10.1159/000365221.
  CrossrefPubMedGoogle Scholar
• 36 Koethe D, Rohleder C, Kracht L. et al. Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state. Front Psychiatry 2023; 14: 1088459 DOI: 10.3389/fpsyt.2023.1088459.
  CrossrefPubMedGoogle Scholar
• 37 Bhattacharyya S, Wilson R, Appiah-Kusi E. et al. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: A randomized clinical trial. JAMA Psychiatry 2018; 75: 1107-1117 DOI: 10.1001/jamapsychiatry.2018.2309.
  CrossrefPubMedGoogle Scholar
• 38 Appiah-Kusi E, Petros N, Wilson R. et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl) 2020; 237: 1121-1130 DOI: 10.1007/s00213-019-05442-6.
  CrossrefPubMedGoogle Scholar
• 39 Davies C, Appiah-Kusi E, Wilson R. et al. Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: A preliminary report. Eur Arch Psychiatry Clin Neurosci 2022; 272: 461-475 DOI: 10.1007/s00406-021-01318-z.
  CrossrefPubMedGoogle Scholar
• 40 Behringer K. Die Bedeutung der Rauschgiftversuche fuer die Klinik. Archiv fuer Neurologie 1932; 28: 1-17
  PubMedGoogle Scholar
• 41 Koethe D, Hoyer C, Leweke FM. The endocannabinoid system as a target for modelling psychosis. Psychopharmacology 2009; 206: 551-561 DOI: 10.1007/s00213-009-1591-7.
  CrossrefPubMedGoogle Scholar
• 42 Murray RM, Forti MD. Cannabis and psychosis: What degree of proof do we require?. Biol Psychiatry 2016; 79: 514-515 DOI: 10.1016/j.biopsych.2016.02.005.
  CrossrefPubMedGoogle Scholar
• 43 Borgwardt SJ, Allen P, Bhattacharyya S. et al. Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: Effects during response inhibition. Biol Psychiatry 2008; 64: 966-973 DOI: 10.1016/j.biopsych.2008.05.011.
  CrossrefPubMedGoogle Scholar
• 44 Bhattacharyya S, Morrison PD, Fusar-Poli P. et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacol 2010; 35: 764-774 DOI: 10.1038/npp.2009.184.
  CrossrefPubMedGoogle Scholar
• 45 Winton-Brown TT, Allen P, Bhattacharyya S. et al. Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: An FMRI study. Neuropsychopharmacol 2011; 36: 1340-1348 DOI: 10.1038/npp.2011.17.
  CrossrefPubMedGoogle Scholar
• 46 Grimm O, Löffler M, Kamping S. et al. Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity. Eur Neuropsychopharmacol 2018; 28: 841-849 DOI: 10.1016/j.euroneuro.2018.04.004.
  CrossrefPubMedGoogle Scholar
• 47 Wilson R, Bossong MG, Appiah-Kusi E. et al. Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. Transl Psychiatry 2019; 9: 203 DOI: 10.1038/s41398-019-0534-2.
  CrossrefPubMedGoogle Scholar
• 48 Davies C, Wilson R, Appiah-Kusi E. et al. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl Psychiatry 2020; 10: 311 DOI: 10.1038/s41398-020-0862-2.
  CrossrefPubMedGoogle Scholar
• 49 O’Neill A, Wilson R, Blest-Hopley G. et al. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med 2021; 51: 596-606 DOI: 10.1017/s0033291719003519.
  CrossrefPubMedGoogle Scholar
• 50 Carey KB, Purnine DM, Maisto SA. et al. Treating substance abuse in the context of severe and persistent mental illness Clinicians’ perspectives. J Subst Abus Treat 2000; 19: 189-198 DOI: 10.1016/s0740-5472(00)00094-5.
  CrossrefPubMedGoogle Scholar
• 51 Manzanares J, Cabañero D, Puente N. et al. Role of the endocannabinoid system in drug addiction. Biochem Pharmacol 2018; 157: 108-121 DOI: 10.1016/j.bcp.2018.09.013.
  CrossrefPubMedGoogle Scholar
• 52 Crippa JAS, Zuardi AW, Hallak JEC. et al. Oral cannabidiol does not convert to Δ⁸-THC or Δ⁹-THC in humans: A pharmacokinetic study in healthy subjects. Cannabis Cannabinoid Res 2020; 5: 89-98 DOI: 10.1089/can.2019.0024.
  CrossrefPubMedGoogle Scholar
• 53 Babalonis S, Haney M, Malcolm RJ. et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depen 2017; 172: 9-13 DOI: 10.1016/j.drugalcdep.2016.11.030.
  CrossrefPubMedGoogle Scholar
• 54 Lawn W, Hill J, Hindocha C. et al. The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers. J Psychopharmacol 2020; 34: 969-980 DOI: 10.1177/0269881120944148.
  CrossrefPubMedGoogle Scholar
• 55 Crippa JAS, Hallak JEC, Machado-de-Sousa JP. et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: A case report. J Clin Pharm Ther 2013; 38: 162-164 DOI: 10.1111/jcpt.12018.
  CrossrefPubMedGoogle Scholar
• 56 Shannon S, Opila-Lehman J. Cannabidiol oil for decreasing addictive use of marijuana: A case report. Integr Med (Encinitas, Calif) 2015; 14: 31-35
  PubMedGoogle Scholar
• 57 Freeman TP, Hindocha C, Baio G. et al. Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry 2020; 7: 865-874 DOI: 10.1016/s2215-0366(20)30290-x.
  CrossrefPubMedGoogle Scholar
• 58 Lees R, Hines LA, Hindocha C. et al. Effect of four-week cannabidiol treatment on cognitive function: Secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder. Psychopharmacology (Berl) 2023; 240: 337-346 DOI: 10.1007/s00213-022-06303-5.
  CrossrefPubMedGoogle Scholar
• 59 Hua DY-H, Hindocha C, Baio G. et al. Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: Findings from a randomised clinical trial for the treatment of cannabis use disorder. Transl Psychiatry 2023; 13: 131 DOI: 10.1038/s41398-023-02410-9.
  CrossrefPubMedGoogle Scholar
• 60 de Meneses-Gaya C, Crippa JA, Hallak JE. et al. Cannabidiol for the treatment of crack-cocaine craving: An exploratory double-blind study. Braz J Psychiatry 2021; 43: 467-476 DOI: 10.1590/1516-4446-2020-1416.
  CrossrefPubMedGoogle Scholar
• 61 Mongeau-Pérusse V, Brissette S, Bruneau J. et al. Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: A randomized placebo-controlled trial. Addiction 2021; 116: 2431-2442 DOI: 10.1111/add.15417.
  CrossrefPubMedGoogle Scholar
• 62 Rizkallah E, Mongeau-Pérusse V, Lamanuzzi L. et al. Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. Pharmacol Biochem Behav 2022; 216: 173376 DOI: 10.1016/j.pbb.2022.173376.
  CrossrefPubMedGoogle Scholar
• 63 Mongeau-Pérusse V, Rizkallah E, Morissette F. et al. Cannabidiol effect on anxiety symptoms and stress response in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. J Addict Med 2022; 16: 521-526 DOI: 10.1097/adm.0000000000000959.
  CrossrefPubMedGoogle Scholar
• 64 Morgan CJA, Das RK, Joye A. et al. Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings. Addict Behav 2013; 38: 2433-2436 DOI: 10.1016/j.addbeh.2013.03.011.
  CrossrefPubMedGoogle Scholar
• 65 Hindocha C, Freeman TP, Grabski M. et al. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction 2018; 113: 1696-1705 DOI: 10.1111/add.14243.
  CrossrefPubMedGoogle Scholar
• 66 Hurd YL, Spriggs S, Alishayev J. et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled Trial. Am J Psychiatry 2019; 176: 911-922 DOI: 10.1176/appi.ajp.2019.18101191.
  CrossrefPubMedGoogle Scholar
• 67 Bajor LA, Balsara C, Osser DN. An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update. Psychiatry Res 2022; 317: 114840 DOI: 10.1016/j.psychres.2022.114840.
  CrossrefPubMedGoogle Scholar
• 68 Lutz B, Marsicano G, Maldonado R. et al. The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci 2015; 16: 705-718 DOI: 10.1038/nrn4036.
  CrossrefPubMedGoogle Scholar
• 69 Micale V, Drago F. Endocannabinoid system, stress and HPA axis. Eur J Pharmacol 2018; 834: 230-239 DOI: 10.1016/j.ejphar.2018.07.039.
  CrossrefPubMedGoogle Scholar
• 70 Schaefer C, Enning F, Mueller JK. et al. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. Eur Arch Psychiatry Clin Neurosci 2014; 264: 459-463 DOI: 10.1007/s00406-013-0470-8.
  CrossrefPubMedGoogle Scholar
• 71 Hauer D, Schelling G, Gola H. et al. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS ONE 2013; 8: e62741 DOI: 10.1371/journal.pone.0062741.
  CrossrefPubMedGoogle Scholar
• 72 Wilker S, Pfeiffer A, Elbert T. et al. Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Psychoneuroendocrinology 2016; 67: 198-206 DOI: 10.1016/j.psyneuen.2016.02.010.
  CrossrefPubMedGoogle Scholar
• 73 Neumeister A, Normandin MD, Pietrzak RH. et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study. Mol Psychiatr 2013; 18: 1034-1040 DOI: 10.1038/mp.2013.61.
  CrossrefPubMedGoogle Scholar
• 74 Spinella TC, Stewart SH, Naugler J. et al. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: A randomized crossover study. Psychopharmacology (Berl) 2021; 238: 1965-1977 DOI: 10.1007/s00213-021-05823-w.
  CrossrefPubMedGoogle Scholar
• 75 Zuardi AW, Shirakawa I, Finkelfarb E. et al. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982; 76: 245-250 DOI: 10.1007/bf00432554.
  CrossrefPubMedGoogle Scholar
• 76 Zuardi AW, Cosme RA, Graeff FG. et al. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993; 7: 82-88 DOI: 10.1177/026988119300700112.
  CrossrefPubMedGoogle Scholar
• 77 Linares IM, Zuardi AW, Pereira LC. et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry 2018; 41: 9-14 DOI: 10.1590/1516-4446-2017-0015.
  CrossrefPubMedGoogle Scholar
• 78 de S Crippa JA, Zuardi AW, Garrido GEJ. et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacol 2004; 29: 417-426 DOI: 10.1038/sj.npp.1300340.
  CrossrefPubMedGoogle Scholar
• 79 Fusar-Poli P, Crippa JA, Bhattacharyya S. et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66: 95-105 DOI: 10.1001/archgenpsychiatry.2008.519.
  CrossrefPubMedGoogle Scholar
• 80 Fusar-Poli P, Allen P, Bhattacharyya S. et al. Modulation of effective connectivity during emotional processing by delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010; 13: 421-432 DOI: 10.1017/s1461145709990617.
  CrossrefPubMedGoogle Scholar
• 81 Bloomfield MAP, Yamamori Y, Hindocha C. et al. The acute effects of cannabidiol on emotional processing and anxiety: A neurocognitive imaging study. Psychopharmacology (Berl) 2022; 239: 1539-1549 DOI: 10.1007/s00213-022-06070-3.
  CrossrefPubMedGoogle Scholar
• 82 Taylor L, Gidal B, Blakey G. et al. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 2018; 32: 1053-1067 DOI: 10.1007/s40263-018-0578-5.
  CrossrefPubMedGoogle Scholar
• 83 Birnbaum AK, Karanam A, Marino SE. et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia 2019; 60: 1586-1592 DOI: 10.1111/epi.16093.
  CrossrefPubMedGoogle Scholar
• 84 Crockett J, Critchley D, Tayo B. et al. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia 2020; 61: 267-277 DOI: 10.1111/epi.16419.
  CrossrefPubMedGoogle Scholar
• 85 Rossi GN, Rocha JM, Osório FL. et al. Interactive effects of ayahuasca and cannabidiol in social cognition in healthy volunteers: A pilot, proof-of-concept, feasibility, randomized-controlled trial. J Clin Psychopharmacol 2023; 43: 339-349 DOI: 10.1097/jcp.0000000000001691.
  CrossrefPubMedGoogle Scholar
• 86 Hundal H, Lister R, Evans N. et al. The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol 2018; 32: 276-282 DOI: 10.1177/0269881117737400.
  CrossrefPubMedGoogle Scholar
• 87 Das RK, Kamboj SK, Ramadas M. et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl) 2013; 226: 781-792 DOI: 10.1007/s00213-012-2955-y.
  CrossrefPubMedGoogle Scholar
• 88 Crippa JAS, Derenusson GN, Ferrari TB. et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J Psychopharmacol 2011; 25: 121-130 DOI: 10.1177/0269881110379283.
  CrossrefPubMedGoogle Scholar
• 89 Bergamaschi MM, Queiroz RHC, Chagas MHN. et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011; 36: 1219-1226 DOI: 10.1038/npp.2011.6.
  CrossrefPubMedGoogle Scholar
• 90 Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol 2019; 10: 2466 DOI: 10.3389/fpsyg.2019.02466.
  CrossrefPubMedGoogle Scholar
• 91 Kwee CM, Baas JM, van der Flier FE. et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. Eur Neuropsychopharmacol 2022; 59: 58-67 DOI: 10.1016/j.euroneuro.2022.04.003.
  CrossrefPubMedGoogle Scholar
• 92 Berger M, Li E, Rice S. et al. Cannabidiol for treatment-resistant anxiety disorders in young people: An open-label trial. J Clin Psychiatry 2022; 83 DOI: 10.4088/jcp.21m14130.
  CrossrefPubMedGoogle Scholar
• 93 Elms L, Shannon S, Hughes S. et al. Cannabidiol in the treatment of post-traumatic stress disorder: A case series. J Altern Complement Med 2019; 25: 392-397 DOI: 10.1089/acm.2018.0437.
  CrossrefPubMedGoogle Scholar
• 94 Bolsoni LM, Crippa JAS, Hallak JEC. et al. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology (Berl) 2022; 239: 1499-1507 DOI: 10.1007/s00213-021-06043-y.
  CrossrefPubMedGoogle Scholar
• 95 Bolsoni LM, Crippa JAS, Hallak JEC. et al. The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. Braz J Psychiatry 2022; 44: 298-307 DOI: 10.1590/1516-4446-2021-2317.
  CrossrefPubMedGoogle Scholar
• 96 Zwaigenbaum L, Penner M. Autism spectrum disorder: advances in diagnosis and evaluation. BMJ 2018; 361: k1674 DOI: 10.1136/bmj.k1674.
  CrossrefPubMedGoogle Scholar
• 97 Griff JR, Langlie J, Bencie NB. et al. Recent advancements in noninvasive brain modulation for individuals with autism spectrum disorder. Neural Regen Res 2022; 18: 1191-1195 DOI: 10.4103/1673-5374.360163.
  CrossrefPubMedGoogle Scholar
• 98 Karhson DS, Krasinska KM, Dallaire JA. et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism 2018; 9: 18 DOI: 10.1186/s13229-018-0203-y.
  CrossrefPubMedGoogle Scholar
• 99 Pretzsch CM, Freyberg J, Voinescu B. et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacol 2019; 44: 1398-1405 DOI: 10.1038/s41386-019-0333-8.
  CrossrefPubMedGoogle Scholar
• 100 Pretzsch CM, Voinescu B, Mendez MA. et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol 2019; 33: 1141-1148 DOI: 10.1177/0269881119858306.
  CrossrefPubMedGoogle Scholar
• 101 Chadwick VL, Rohleder C, Koethe D. et al. Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Curr Opin Psychiatry 2020; 33: 20-42 DOI: 10.1097/yco.0000000000000562.
  CrossrefPubMedGoogle Scholar
• 102 Viudez-Martínez A, García-Gutiérrez MS, Navarrón CM. et al. Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol 2018; 23: 154-164 DOI: 10.1111/adb.12495.
  CrossrefPubMedGoogle Scholar
• 103 Viudez-Martínez A, García-Gutiérrez MS, Manzanares J. Gender differences in the effects of cannabidiol on ethanol binge drinking in mice. Addict Biol 2020; 25: e12765 DOI: 10.1111/adb.12765.
  CrossrefPubMedGoogle Scholar
• 104 Viudez-Martínez A, García-Gutiérrez MS, Fraguas-Sánchez AI. et al. Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. Br J Pharmacol 2018; 175: 3369-3378 DOI: 10.1111/bph.14380.
  CrossrefPubMedGoogle Scholar
• 105 Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM. et al. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: Preclinical proof of principle. Neuropsychopharmacol 2018; 43: 2036-2045 DOI: 10.1038/s41386-018-0050-8.
  CrossrefPubMedGoogle Scholar
• 106 Pedrazzi JFC, Ferreira FR, Silva-Amaral D. et al. Cannabidiol for the treatment of autism spectrum disorder: Hope or hype. Psychopharmacology 2022; 239: 2713-2734 DOI: 10.1007/s00213-022-06196-4.
  CrossrefPubMedGoogle Scholar
• 107 Silote GP, Sartim A, Sales A. et al. Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. J Chem Neuroanat 2019; 98: 104-116 DOI: 10.1016/j.jchemneu.2019.04.006.
  CrossrefPubMedGoogle Scholar
• 108 Souza JDR, Pacheco JC, Rossi GN. et al. Adverse effects of oral cannabidiol: An updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics 2022; 14: 2598 DOI: 10.3390/pharmaceutics14122598.
  CrossrefPubMedGoogle Scholar
• 109 Huestis MA, Solimini R, Pichini S. et al. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol 2019; 17: 974-989 DOI: 10.2174/1570159x17666190603171901.
  CrossrefPubMedGoogle Scholar
• 110 Leweke FM, Odorfer TM, Bumb JM. Medical needs in the treatment of psychotic disorders. Handb Exp Pharmacol 2012; 165-185 DOI: 10.1007/978-3-642-25761-2_7.
  CrossrefPubMedGoogle Scholar
• 111 Leichsenring F, Steinert C, Rabung S. et al. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: An umbrella review and meta-analytic evaluation of recent meta-analyses. World Psychiatry 2022; 21: 133-145 DOI: 10.1002/wps.20941.
  CrossrefPubMedGoogle Scholar
• 112 Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: State of the art and new directions. Mol Psychiatry 2022; 27: 58-72 DOI: 10.1038/s41380-021-01200-3.
  CrossrefPubMedGoogle Scholar
• 113 Laurentiis AD, Correa F, Solari JF. Endocannabinoid system in the neuroendocrine response to lipopolysaccharide-induced immune challenge. J Endocr Soc 2022; 6: bvac120 DOI: 10.1210/jendso/bvac120.
  CrossrefPubMedGoogle Scholar
• 114 Zdanowicz A, Kaźmierczak W, Wierzbiński P. The endocannabinoid system role in the pathogenesis of obesity and depression. Polski Merkur Lék : organ Polskiego Towar Lék 2015; 39: 61-66
  PubMedGoogle Scholar
• 115 Zubrzycki M, Liebold A, Janecka A. et al. A new face of endocannabinoids in pharmacotherapy. Part II: Role of endocannabinoids in inflammation-derived cardiovaascular diseases. J Physiol Pharmacol : Off J Pol Physiol Soc 2013; 65: 183-191
  PubMedGoogle Scholar
• 116 Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci 2018; 19: 833 DOI: 10.3390/ijms19030833.
  CrossrefPubMedGoogle Scholar
• 117 Giuffrida A, Leweke FM, Gerth CW. et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacol 2004; 29: 2108-2114 DOI: 10.1038/sj.npp.1300558.
  CrossrefPubMedGoogle Scholar
• 118 Potvin S, Mahrouche L, Assaf R. et al. Peripheral endogenous cannabinoid levels are increased in schizophrenia patients evaluated in a psychiatric emergency setting. Front Psychiatry 2020; 11: 628 DOI: 10.3389/fpsyt.2020.00628.
  CrossrefPubMedGoogle Scholar
• 119 Ceccarini J, Hert MD, Winkel RV. et al. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 2013; 79: 304-312 DOI: 10.1016/j.neuroimage.2013.04.052.
  CrossrefPubMedGoogle Scholar
• 120 Koethe D, Giuffrida A, Schreiber D. et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 2009; 194: 371-372 DOI: 10.1192/bjp.bp.108.053843.
  CrossrefPubMedGoogle Scholar